Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma dosed the last subject in its Phase 1b human challenge study (NCT07198139) evaluating CDI-988 as both a preventive and treatment for norovirus, with no serious adverse events reported to date. The randomized, double-blind, placebo-controlled trial is being run at Emory University School of Medicine, dosing healthy subjects ages 18-49 infected with the GII.2 Snow Mountain Virus strain at the 1200 mg dose established as safe in an earlier Phase 1 study in Australia. Preliminary efficacy results are expected in late 2026 or early 2027, and management positions CDI-988 as a potential first-in-class oral antiviral targeting a disease with an estimated 685 million global cases and $60 billion in annual economic impact.

•1mo ago

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Cocrystal Pharma announced the appointment of Dr. Carol Brosgart to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings decades of experience in antiviral drug development from her tenure at Gilead Sciences and advisory roles at the CDC. Her expertise is expected to support the advancement of CDI-988 for norovirus and the company's broader antiviral pipeline.

•2mo ago

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Cocrystal Pharma secured $5 million in gross proceeds through a private placement with OPKO Health, selling 5.47 million shares at the Nasdaq bid price of $0.9134. The investment increases OPKO's position as the company prepares to report topline data from its Phase 1b norovirus trial for lead asset CDI-988 in late 2026. No warrants were issued in the transaction, and proceeds will support the continued development of the antiviral pipeline.

•2mo ago

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Cocrystal Pharma has appointed James Sapirstein as Chief Executive Officer, effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Sapirstein brings extensive experience in antiviral drug development, having led 23 product launches and served as CEO at Contravir Pharmaceuticals and founding CEO of Tobira Therapeutics. Sam Lee transitions to Chief Scientific Officer and Jim Martin remains as CFO, while Sapirstein will also join the Board of Directors.

•4mo ago

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

Cocrystal Pharma announced that its novel direct-acting antivirals demonstrate pan-viral activity against hantavirus, bunyavirus, and influenza in early-stage in vitro studies. The compounds target the L-protein of the viral replication enzyme, showing superior potency with IC50 values below 50 nM against hantaan virus. This discovery expands the company’s pipeline beyond its current Phase 1b norovirus candidate, CDI-988, targeting unmet medical needs with no approved treatments.

•5mo ago

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

Cocrystal Pharma reported Q1 2026 revenue of $225,000 from an NIH SBIR grant, with a net loss of $2.3 million and unrestricted cash of $4.7 million. The company completed enrollment in the first cohort of its Phase 1b norovirus challenge study for CDI-988 and received FDA Fast Track designation for the asset. Management highlighted the innovative study design and the potential for accelerated development, while noting the receipt of initial SBIR funding for its influenza program.

•5mo ago